Guest guest Posted May 23, 2009 Report Share Posted May 23, 2009 Drs. Neil Shah and Feldman both talk about leukemia and Gleevec at the American Society of Hematology (ASH) annual meeting. There is also a podcast available at this same website, but my speakers are out so I read the transcript posted from LLS and pasted some of the quotes. In the media, it is called a teaser, to get your attention. I think you will be interested in reading or listening to all of it, this is only a small part. " Dr. Shah reported that if CML loses a response to Gleevec (relapses) it is most likely due to 1 of 90 identified molecular mutations (changes). Sometimes a safe dose of Gleevec is not able to stop cells from overexpressing (making too much) Bcr-Abl, a cancer-causing protein. " He also praised patients with CML for their participation in clinical trials. Dr, Feldman said, " Gleevec is great, but the big question facing us now is, can we do better? " Very interesting transcript. More at t his website. http://www.leukemia-lymphoma.org/graphics/National/EI2547A6T6CMLNLVol18.pdf FYI, Lottie Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.